BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 19781316)

  • 1. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].
    Xie Y; Liu T; Zhou YJ; Ma HY; Guo YH; Li YP; Cheng WJ; Liu YY; Zhao YX; Shi DM
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jan; 37(1):39-43. PubMed ID: 19671350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
    J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
    Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.
    Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP
    Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction.
    Yan HB; Li SY; Song L; Wang J; Wu Z; Chi YP; Zheng B; Zhao HJ; Li QX; Zhang XJ; Li WZ
    Chin Med J (Engl); 2010 Apr; 123(7):877-83. PubMed ID: 20497681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
    Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of preprocedural troponin-I in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention.
    Napan S; Kashinath RC; Kadri S; Orig MN; Khadra S
    Coron Artery Dis; 2010 Aug; 21(5):261-5. PubMed ID: 20555264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
    Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
    Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
    Riezebos RK; Ronner E; Ter Bals E; Slagboom T; Smits PC; ten Berg JM; Kiemeneij F; Amoroso G; Patterson MS; Suttorp MJ; Tijssen JG; Laarman GJ;
    Heart; 2009 May; 95(10):807-12. PubMed ID: 19098058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
    Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study.
    Zhang Q; Zhang RY; Qiu JP; Jin HG; Zhang JF; Wang XL; Jiang L; Liao ML; Hu J; Ding FH; Zhang JS; Shen WF
    Chin Med J (Engl); 2009 Mar; 122(6):636-42. PubMed ID: 19323926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
    Han YL; Wang B; Li Y; Xu K; Wang SL; Jing QM; Wang ZL; Wang DM; Ma YY; Wang G
    Chin Med J (Engl); 2009 Apr; 122(7):793-7. PubMed ID: 19493391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
    Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
    Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognosis after acute coronary syndrome. Lack of difference according to the sex].
    Bounhoure JP; Farah B; Fajadet J; Marco J
    Bull Acad Natl Med; 2004; 188(3):383-97; discussion 397-9. PubMed ID: 15584651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.